PLXHIGH SIGNALFINANCIAL10-K

PLX experienced a dramatic operational deterioration with net income swinging from $2.9M profit to -$6.6M loss while operating cash flow collapsed from $8.7M positive to -$12.0M negative.

This represents a fundamental shift from profitability to significant losses despite 400% gross profit growth, indicating severe operational inefficiencies or one-time charges that overwhelmed revenue gains. The company's cash position declined 26% while burning through $12M in operating cash flow, raising concerns about financial sustainability and the need for additional funding.

Comparing 2026-03-18 vs 2025-03-17View on EDGAR →
FINANCIAL ANALYSIS

PLX showed mixed results with gross profit surging 400% to $4.0M and accounts receivable tripling, suggesting strong revenue growth, but this was completely offset by a 51% spike in R&D expenses to $19.6M. The company swung from $2.9M net income and $8.7M positive operating cash flow to -$6.6M losses and -$12.0M cash burn, while cash reserves dropped 26% to $14.7M. Despite revenue momentum, the dramatic deterioration in profitability and cash generation signals serious operational challenges and potential funding needs.

FINANCIAL STATEMENT CHANGES
Gross Profit
P&L
+400.7%
$801K$4.0M

Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.

Net Income
P&L
-325.2%
$2.9M-$6.6M

Net income declined 325.2% — review whether driven by operations, interest costs, or non-recurring items.

Operating Income
P&L
-240.4%
$3.9M-$5.5M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Operating Cash Flow
Cash Flow
-238.3%
$8.7M-$12.0M

Operating cash flow fell 238.3% — earnings quality concerns; investigate working capital changes and non-cash items.

Accounts Receivable
Balance Sheet
+203.9%
$2.9M$8.8M

Receivables surged 203.9% — revenue recognized but not yet collected; watch for collection issues or channel stuffing.

R&D Expense
P&L
+50.9%
$13.0M$19.6M

R&D investment increased 50.9% — signals commitment to future product development, though near-term margin impact.

Capital Expenditure
Cash Flow
+27.8%
$1.3M$1.6M

Capex increased 27.8% — ongoing investment in capacity or infrastructure for future growth.

Cash & Equivalents
Balance Sheet
-25.7%
$19.8M$14.7M

Cash decreased 25.7% — monitor burn rate and upcoming capital needs.

Inventory
Balance Sheet
+21.1%
$21.2M$25.7M

Inventory built 21.1% — monitor whether demand supports this build or if write-downs may follow.

Total Liabilities
Balance Sheet
+12.9%
$30.2M$34.1M

Liabilities increased 12.9% — monitor debt-to-equity ratio and interest coverage.

LANGUAGE CHANGES
NEW — 2026-03-18
PRIOR — 2025-03-17
ADDED
On March 1, 2026, approximately 80,571,642 shares of the Registrant s common stock, par value $0.001 per share, were outstanding.
Market for Registrant s Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities 59 Item 6.
and its consolidated subsidiary, and Protalix or Protalix Ltd.
These and other risks and uncertainties are detailed under the Risk Factors section of this Annual Report and are described from time to time in the reports we file with the U.S.
Business We are a commercial stage biopharmaceutical company focused on the discovery, development, production and commercialization of innovative therapeutics for rare diseases with significant unmet needs.
+7 more — sign up free →
REMOVED
On March 14, 2025, approximately 78,032,585 shares of the Registrant s common stock, par value $0.001 per share, were outstanding.
Market for Registrant s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 63 Item 6.
and its consolidated subsidiaries, and Protalix or Protalix Ltd.
Business We are a commercial stage biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced via our proprietary ProCellEx plant cell-based protein expression system.
Our unique expression system represents a new method for developing recombinant proteins in an industrial-scale manner.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →